Metabolic health protocols covering insulin sensitivity, glucose homeostasis, and energy metabolism with peptides. GLP-1 agonism is the headline. The full picture is three distinct peptide classes acting on glucose metabolism through different mechanisms. Tirzepatide's insulin-sensitivity effect comes mostly from direct metabolic reprogramming, not weight loss. MOTS-c bypasses receptors entirely as a mitochondrial messenger that mimics exercise at the cellular level. This hub covers the full metabolic stack from gut healing to appetite signalling.
Our DNA is not a static blueprint of decline but a dynamic epigenetic landscape that can be re-tuned through precise molecular signaling.
For the sophisticated health optimizer, the narrative of the last few years has been dominated by the "incretin revolution." We have watched semaglutide and tirzepatide dismantle the traditional "willpower" myth of obesity. Yet, a frustrating biological reality has emerged: the "weight loss wall." Enter Retatrutide — the world's first triple agonist designed to re-engineer the metabolic equation entirely.
A 16-amino-acid mitochondrial messenger that mimics exercise at the cellular level — activating AMPK, reprogramming metabolism, and writing survival instructions directly into the nucleus. The science is striking. The stability problem is brutal.
The GLP-1 receptor agonist reshaping metabolic medicine, from weight loss to cardiovascular protection, liver repair, and beyond.
The first dual-action incretin that outpaces single-agonist therapy across weight, glucose, heart failure, and sleep apnoea, while forcing medicine to reckon with the musculoskeletal cost of rapid metabolic transformation.
The oral compound that reliably raises GH and IGF-1 to youthful levels, delivers measurable gains in lean mass and sleep architecture, yet consistently failed to translate those biomarker wins into functional outcomes across 30 years of clinical trials.
A 16-amino-acid fragment of human growth hormone engineered to trigger fat metabolism without activating the GH receptor, AOD-9604 cleared early clinical trials for obesity before its pivotal Phase IIb collapsed under a placebo response. Now stripped of FDA Category 2 status and banned by WADA, its most interesting data may be in a direction nobody expected: cartilage repair.
The biochemical cofactors your body needs to support Retatrutide therapy.
The biochemical cofactors your body needs to support Semaglutide therapy.
The biochemical cofactors your body needs to support Tirzepatide therapy.
The biochemical cofactors your body needs to support AOD-9604 (hGH Fragment 176-191) therapy.